Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of venous
thromboembolism events (VTE). This study performed a systematic review in …

Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …

Infection with the SARS-CoV-2 virus, resulting in COVID-19 disease, has presented a
unique scenario associated with high rates of thrombosis. The risk of venous thrombosis is …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …

Background Pulmonary embolisms are frequently and prognostically in individuals infected
by coronavirus disease 2019 (COVID-19); the incidence of pulmonary embolisms is varied …

Objective Coagulation and inflammatory parameters are mildly altered in children with
SARS-CoV-2 (COVID-19) infection, and laboratory evidence of a proinflammatory and …

Abstract On March 11, 2020, the World Health Organization declared Coronavirus Disease
2019 (COVID-19) a pandemic. Till now, it affected 452.4 million (Spain, 11.18 million) …

BACKGROUND Coronavirus disease 2019 (COVID-19) has left a significant impact on the
world's health, economic and political systems; as of November 20, 2020, more than 57 …

Background COVID-19 appears to be associated with a high risk of venous
thromboembolism (VTE). We aimed to systematically review and meta-analyze the risk of …

Objective We have summarized the incidence, anticoagulation panels, laboratory
characteristics, and mortality of venous thromboembolism (VTE) in hospitalized patients with …